State Medicaid program to benefit from settlement
BISMARCK — North Dakota’s Medicaid program will receive nearly $3 million as part of a $1.2 billion national settlement that resolves claims against Johnson & Johnson and a subsidiary for their marketing of the antipsychotic drugs Risperdal and Invega.
Are you a newspaper subscriber but you don't have a Digital Access account yet? Activate your account.
You will need your subscription account number and phone number. Not sure if you have an account? Call (701) 225-8111 and we can help you.